Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-cash Items (2016 - 2019)

Akebia Therapeutics (AKBA) has disclosed Non-cash Items for 4 consecutive years, with $3.2 million as the latest value for Q4 2019.

  • Quarterly Non-cash Items rose 34.95% to $3.2 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2019, up 34.95% year-over-year, with the annual reading at $3.2 million for FY2019, 34.95% up from the prior year.
  • Non-cash Items for Q4 2019 was $3.2 million at Akebia Therapeutics, up from $2.4 million in the prior quarter.
  • The five-year high for Non-cash Items was $21.9 million in Q4 2017, with the low at $2.4 million in Q4 2018.
  • Average Non-cash Items over 4 years is $9.5 million, with a median of $6.8 million recorded in 2016.
  • The sharpest move saw Non-cash Items surged 110.13% in 2017, then plummeted 89.28% in 2018.
  • Over 4 years, Non-cash Items stood at $10.4 million in 2016, then soared by 110.13% to $21.9 million in 2017, then tumbled by 89.28% to $2.4 million in 2018, then skyrocketed by 34.95% to $3.2 million in 2019.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $3.2 million, $2.4 million, and $21.9 million for Q4 2019, Q4 2018, and Q4 2017 respectively.